95 related articles for article (PubMed ID: 20026245)
1. Trace amine metabolism in Parkinson's disease: low circulating levels of octopamine in early disease stages.
D'Andrea G; Nordera G; Pizzolato G; Bolner A; Colavito D; Flaibani R; Leon A
Neurosci Lett; 2010 Jan; 469(3):348-51. PubMed ID: 20026245
[TBL] [Abstract][Full Text] [Related]
2. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
[TBL] [Abstract][Full Text] [Related]
3. Abnormal platelet trace amine profiles in migraine with and without aura.
D'Andrea G; Granella F; Leone M; Perini F; Farruggio A; Bussone G
Cephalalgia; 2006 Aug; 26(8):968-72. PubMed ID: 16886933
[TBL] [Abstract][Full Text] [Related]
4. Trace amines differentially regulate adult locomotor activity, cocaine sensitivity, and female fertility in Drosophila melanogaster.
Hardie SL; Zhang JX; Hirsh J
Dev Neurobiol; 2007 Sep; 67(10):1396-405. PubMed ID: 17638385
[TBL] [Abstract][Full Text] [Related]
5. The role of tyrosine metabolism in the pathogenesis of chronic migraine.
D'Andrea G; D'Amico D; Bussone G; Bolner A; Aguggia M; Saracco MG; Galloni E; De Riva V; Colavito D; Leon A; Rosteghin V; Perini F
Cephalalgia; 2013 Aug; 33(11):932-7. PubMed ID: 23493762
[TBL] [Abstract][Full Text] [Related]
6. Expression analysis of suppression of tumorigenicity 13 gene in patients with Parkinson's disease.
Shadrina MI; Filatova EV; Karabanov AV; Slominsky PA; Illarioshkin SN; Ivanova-Smolenskaya IA; Limborska SA
Neurosci Lett; 2010 Apr; 473(3):257-9. PubMed ID: 20193743
[TBL] [Abstract][Full Text] [Related]
7. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
Huot P; Lévesque M; Parent A
Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
[TBL] [Abstract][Full Text] [Related]
8. Different Circulating Trace Amine Profiles in De Novo and Treated Parkinson's Disease Patients.
D'Andrea G; Pizzolato G; Gucciardi A; Stocchero M; Giordano G; Baraldi E; Leon A
Sci Rep; 2019 Apr; 9(1):6151. PubMed ID: 30992490
[TBL] [Abstract][Full Text] [Related]
9. The relation of testosterone levels with fatigue and apathy in Parkinson's disease.
Kenangil G; Orken DN; Ur E; Forta H; Celik M
Clin Neurol Neurosurg; 2009 Jun; 111(5):412-4. PubMed ID: 19131155
[TBL] [Abstract][Full Text] [Related]
10. Circulating interleukin-10 and interleukin-12 in Parkinson's disease.
Rentzos M; Nikolaou C; Andreadou E; Paraskevas GP; Rombos A; Zoga M; Tsoutsou A; Boufidou F; Kapaki E; Vassilopoulos D
Acta Neurol Scand; 2009 May; 119(5):332-7. PubMed ID: 18976327
[TBL] [Abstract][Full Text] [Related]
11. [Case-control study of markers of oxidative stress and metabolism of blood iron in Parkinson's disease].
Larumbe Ilundáin R; Ferrer Valls JV; Viñes Rueda JJ; Guerrero D; Fraile P
Rev Esp Salud Publica; 2001; 75(1):43-53. PubMed ID: 11400414
[TBL] [Abstract][Full Text] [Related]
12. Plasma alpha-synuclein is decreased in subjects with Parkinson's disease.
Li QX; Mok SS; Laughton KM; McLean CA; Cappai R; Masters CL; Culvenor JG; Horne MK
Exp Neurol; 2007 Apr; 204(2):583-8. PubMed ID: 17258710
[TBL] [Abstract][Full Text] [Related]
13. Poor metabolization of n-hexane in Parkinson's disease.
Canesi M; Perbellini L; Maestri L; Silvani A; Zecca L; Bet L; Pezzoli G
J Neurol; 2003 May; 250(5):556-60. PubMed ID: 12736734
[TBL] [Abstract][Full Text] [Related]
14. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.
Kish SJ; Tong J; Hornykiewicz O; Rajput A; Chang LJ; Guttman M; Furukawa Y
Brain; 2008 Jan; 131(Pt 1):120-31. PubMed ID: 17956909
[TBL] [Abstract][Full Text] [Related]
15. Plasma aminopeptidase activities in Parkinson's disease.
Banegas I; Barrero F; Durán R; Morales B; Luna JD; Prieto I; Ramírez M; Alba F; Vives F
Horm Metab Res; 2006 Nov; 38(11):758-60. PubMed ID: 17111304
[TBL] [Abstract][Full Text] [Related]
16. [Plasma atrial natriuretic peptide (ANP) levels in Parkinson's disease--with special reference to foot edema].
Maki T; Sonoda Y; Sugita K
Rinsho Shinkeigaku; 1990 Jun; 30(6):605-9. PubMed ID: 2146055
[TBL] [Abstract][Full Text] [Related]
17. Is there an association between the level of high-sensitivity C-reactive protein and idiopathic Parkinson's disease? A comparison of Parkinson's disease patients, disease controls and healthy individuals.
Song IU; Kim JS; Chung SW; Lee KS
Eur Neurol; 2009; 62(2):99-104. PubMed ID: 19521085
[TBL] [Abstract][Full Text] [Related]
18. Circulating interleukin-15 and RANTES chemokine in Parkinson's disease.
Rentzos M; Nikolaou C; Andreadou E; Paraskevas GP; Rombos A; Zoga M; Tsoutsou A; Boufidou F; Kapaki E; Vassilopoulos D
Acta Neurol Scand; 2007 Dec; 116(6):374-9. PubMed ID: 17986095
[TBL] [Abstract][Full Text] [Related]
19. The validity of the GaitRite and the Functional Ambulation Performance scoring system in the analysis of Parkinson gait.
Nelson AJ; Zwick D; Brody S; Doran C; Pulver L; Rooz G; Sadownick M; Nelson R; Rothman J
NeuroRehabilitation; 2002; 17(3):255-62. PubMed ID: 12237507
[TBL] [Abstract][Full Text] [Related]
20. Elusive amines and primary headaches: historical background and prospectives.
D'Andrea G; Terrazzino S; Fortin D; Cocco P; Balbi T; Leon A
Neurol Sci; 2003 May; 24 Suppl 2():S65-7. PubMed ID: 12811595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
